Citations (111)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (26)
Yan Wu, Shan Liu, Dongmei Wang & Xinjie Yao. (2023) Acute Myeloid Leukemia Secondary to Chronic Lymphocytic Leukemia After Prolonged Chlorambucil Therapy: A Case Report. Pharmacogenomics and Personalized Medicine 16, pages 401-405.
Read now
Read now
Yingyue Liu, Yurou Chu, Jiarui Liu, Xueling Ge, Mei Ding, Peipei Li, Fang Liu, Xiangxiang Zhou & Xin Wang. (2023) Incidence and mortality of second primary malignancies after lymphoma: a population-based analysis. Annals of Medicine 55:2.
Read now
Read now
Doreen G. Te Raa, Lina van der Straten, Michel van Gelder, Sabina Kersting, Mark-David Levin, Rogier Mous, Hanneke M. van der Straaten, Marten R. Nijziel, Ellen van der Spek, Eduardus F. M Posthuma, Hein P.J Visser, Marjolein van der Klift, Koen de Heer, Mar Bellido, Jeanette K. Doorduijn, Anke H.W Bruns, Reinier A. P Raijmakers & Arnon P. Kater. (2022) Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group. Leukemia & Lymphoma 63:10, pages 2276-2289.
Read now
Read now
Othman Salim Akhtar, Adrienne Groman, Anil Singh, Paola Ghione, Ian Lund, Francisco J. Hernandez-Ilizaliturri & Pallawi Torka. (2022) Frequency and timing of other primary cancers in patients with chronic lymphocytic leukemia (CLL): a 17-year longitudinal study. Leukemia & Lymphoma 63:5, pages 1127-1136.
Read now
Read now
Marcell Csanádi, Tamás Ágh, Attila Tordai, Christoph Tapprich, Zoltán Vokó & Kostas Stamatopoulos. (2022) Secondary primary malignancies after treatment with chemo-immunotherapy in treatment-naïve patients with CLL: a systematic literature review. Expert Review of Hematology 15:3, pages 273-284.
Read now
Read now
Ankit Shah & Jacqueline C Barrientos. (2021) Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib. OncoTargets and Therapy 14, pages 2109-2119.
Read now
Read now
Sanjal Desai, Clifton Mo, Erika M. Gaglione, Constance M. Yuan, Maryalice Stetler-Stevenson, Xin Tian, Irina Maric, Laura Wake, Mohammed Z. Farooqui, Dennis C. Drinkwater, Susan Soto, Janet Valdez, Thomas E. Hughes, Pia Nierman, Jennifer Lotter, Gerald E. Marti, Christopher Pleyer, Clare Sun, Jeanine Superata, Cydney Nichols, Sarah E. M. Herman, Margaret A. Lindorfer, Ronald P. Taylor, Adrian Wiestner & Inhye E. Ahn. (2021) Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study. Leukemia & Lymphoma 62:8, pages 1816-1827.
Read now
Read now
Sean Harrop, Aaron Polliack & Constantine S. Tam. (2021) Chronic lymphoproliferative disorders and secondary cancers in the era of purine analogues and beyond. Leukemia & Lymphoma 62:4, pages 771-778.
Read now
Read now
Seema A. Bhat & Jennifer A. Woyach. (2020) Changing landscape of frontline therapy in chronic lymphocytic leukemia. Leukemia & Lymphoma 61:3, pages 525-535.
Read now
Read now
Yasir Khan, Yung Lyou, Monica El-Masry & Susan O’Brien. (2020) Reassessing the role of chemoimmunotherapy in chronic lymphocytic leukemia. Expert Review of Hematology 13:1, pages 31-38.
Read now
Read now
Michèle Stella Majoumouo, Marius Belmondo Tincho, Thureyah Morris, Donavon Charles Hiss, Fabrice Fekam Boyom & Chitra Mandal. (2020) Antiproliferative potential of methanolic and aqueous extracts and their methanolic fractions derived from fruits of Bersama engleriana against a panel of four cancer cell lines. Cogent Biology 6:1.
Read now
Read now
Yan-Hua Zheng, Li Xu, Chun Cao, Juan Feng, Hai-Long Tang, Mi-Mi Shu, Guang-Xun Gao & Xie-Qun Chen. (2019) Rituximab-based combination therapy in patients with Waldenström macroglobulinemia: a systematic review and meta-analysis. OncoTargets and Therapy 12, pages 2751-2766.
Read now
Read now
Stephen P. Mulligan, Stephen Shumack & Alexander Guminski. (2019) Chronic lymphocytic leukemia, skin and other second cancers. Leukemia & Lymphoma 60:13, pages 3104-3106.
Read now
Read now
Ganchimeg Ishdorj, Sara Beiggi, Zoann Nugent, Erin Streu, Versha Banerji, Dhali Dhaliwal, Salah M. Mahmud, Aaron J. Marshall, Spencer B. Gibson, Marni C. Wiseman & James B. Johnston. (2019) Risk factors for skin cancer and solid tumors in newly diagnosed patients with chronic lymphocytic leukemia and the impact of skin surveillance on survival. Leukemia & Lymphoma 60:13, pages 3204-3213.
Read now
Read now
Estella Matutes & Aaron Polliack. (2019) CLL and CML sometimes meet and circulate together. Leukemia & Lymphoma 60:6, pages 1352-1353.
Read now
Read now
Marina Deodato, Anna Maria Frustaci, Giulia Zamprogna, Roberto Cairoli, Marco Montillo & Alessandra Tedeschi. (2019) Ibrutinib for the treatment of chronic lymphocytic leukemia. Expert Review of Hematology 12:5, pages 273-284.
Read now
Read now
Nathalie Denizon, Alix Baugier de Materre, Mustapha Alani, Habib Ghnaya, Jonathan Farhi, Anne Besançon & Kamel Laribi. (2018) Significant impact of immunosuppression on the incidence of secondary malignancies following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with indolent B-cell neoplasms. Leukemia & Lymphoma 59:11, pages 2711-2714.
Read now
Read now
Henriette Huber, Simone Edenhofer, Sven Estenfelder & Stephan Stilgenbauer. (2017) Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia. OncoTargets and Therapy 10, pages 645-656.
Read now
Read now
Andrew Aw & Jennifer R. Brown. (2017) The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia. Leukemia & Lymphoma 58:10, pages 2287-2297.
Read now
Read now
Anna Piggin, Emma Bayly & Constantine S. Tam. (2017) Novel agents versus chemotherapy as frontline treatment of CLL. Leukemia & Lymphoma 58:6, pages 1320-1324.
Read now
Read now
Mohamed Abd El-Fattah. (2017) Risk of second cancers in survivors of prolymphocytic leukemia: a SEER data analysis. Acta Oncologica 56:1, pages 115-117.
Read now
Read now
Prithviraj Bose, Varsha V. Gandhi & Michael J. Keating. (2016) Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. Expert Opinion on Drug Metabolism & Toxicology 12:11, pages 1381-1392.
Read now
Read now
Constantine S. Tam & Aaron Polliack. (2016) A novel way to consolidate incomplete responses in chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia & Lymphoma 57:3, pages 503-504.
Read now
Read now
Mazyar Shadman, Ajay K. Gopal, Britt Kammerer, Pamela S. Becker, David G. Maloney, Barbara Pender, Andrei R. Shustov, Oliver W. Press & John M. Pagel. (2016) Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission. Leukemia & Lymphoma 57:3, pages 572-576.
Read now
Read now
Jasleen K. Randhawa & Alessandra Ferrajoli. (2016) A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia. Expert Review of Hematology 9:3, pages 235-244.
Read now
Read now
Petra Langerbeins, Christian Maurer, Paula Cramer, Barbara Eichhorst & Michael Hallek. (2015) Second cancers in chronic lymphocytic leukemia: growing importance in the era of improved treatment outcomes. Leukemia & Lymphoma 56:6, pages 1575-1576.
Read now
Read now
Articles from other publishers (85)
Rahul Mishra, Danai Dima, Sumukh A. Kumar, Agrima Mian, Alankrita Taneja, Rahul Karna, Paolo F. Caimi, Brian T. Hill, Robert Dean & Deepa Jagadeesh. (2023) A population level analysis of second hematological malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma survivors in the era of targeted therapies. Hematological Oncology 41:5, pages 884-893.
Crossref
Crossref
Thomas Chatzikonstantinou, Lydia Scarfò, Georgios Karakatsoulis, Eva Minga, Dimitra Chamou, Gloria Iacoboni, Jana Kotaskova, Christos Demosthenous, Lukas Smolej, Stephen Mulligan, Miguel Alcoceba, Salem Al-Shemari, Thérèse Aurran-Schleinitz, Francesca Bacchiarri, Mar Bellido, Fontanet Bijou, Anne Calleja, Angeles Medina, Mehreen Ali Khan, Ramona Cassin, Sofia Chatzileontiadou, Rosa Collado, Amy Christian, Zadie Davis, Maria Dimou, David Donaldson, Gimena Dos Santos, Barbara Dreta, Maria Efstathopoulou, Shaimaa El-Ashwah, Alicia Enrico, Alberto Fresa, Sara Galimberti, Andrea Galitzia, Rocío García-Serra, Eva Gimeno, Isabel González-Gascón-y-Marín, Alessandro Gozzetti, Valerio Guarente, Romain Guieze, Ajay Gogia, Ritu Gupta, Sean Harrop, Eleftheria Hatzimichael, Yair Herishanu, José-Ángel Hernández-Rivas, Luca Inchiappa, Ozren Jaksic, Susanne Janssen, Elżbieta Kalicińska, Laribi Kamel, Volkan Karakus, Arnon P. Kater, Bonnie Kho, Maria Kislova, Eliana Konstantinou, Maya Koren-Michowitz, Ioannis Kotsianidis, Robert J. Kreitman, Jorge Labrador, Deepesh Lad, Mark-David Levin, Ilana Levy, Thomas Longval, Alberto Lopez-Garcia, Juan Marquet, Lucia Martin-Rodríguez, Marc Maynadié, Stanislava Maslejova, Carlota Mayor-Bastida, Biljana Mihaljevic, Ivana Milosevic, Fatima Miras, Riccardo Moia, Marta Morawska, Roberta Murru, Uttam Kumar Nath, Almudena Navarro-Bailón, Ana C. Oliveira, Jacopo Olivieri, David Oscier, Irina Panovska-Stavridis, Maria Papaioannou, Tomas Papajík, Zuzana Kubova, Punyarat Phumphukhieo, Cheyenne Pierie, Anna Puiggros, Lata Rani, Gianluigi Reda, Gian Matteo Rigolin, Rosa Ruchlemer, Marcos Daniel de Deus Santos, Mattia Schipani, Annett Schiwitza, Yandong Shen, Martin Simkovic, Svetlana Smirnova, Dina Sameh Abdelrahman Soliman, Martin Spacek, Tamar Tadmor, Kristina Tomic, Eric Tse, Theodoros Vassilakopoulos, Andrea Visentin, Candida Vitale, Julia von Tresckow, George Vrachiolias, Vojin Vukovic, Renata Walewska, Ewa Wasik-Szczepanek, Zhenshu Xu, Munci Yagci, Lucrecia Yañez, Mohamed Yassin, Jana Zuchnicka, Maria Angelopoulou, Darko Antic, Bella Biderman, Mark Catherwood, Rainer Claus, Marta Coscia, Antonio Cuneo, Fatih Demirkan, Blanca Espinet, Gianluca Gaidano, Olga B. Kalashnikova, Luca Laurenti, Eugene Nikitin, Gerassimos A. Pangalis, Panagiotis Panagiotidis, Viola Maria Popov, Sarka Pospisilova, Paolo Sportoletti, Niki Stavroyianni, Constantine Tam, Livio Trentin, Anastasia Chatzidimitriou, Francesc Bosch, Michael Doubek, Paolo Ghia & Kostas Stamatopoulos. (2023) Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY. eClinicalMedicine 65, pages 102307.
Crossref
Crossref
Bowen He, Junid A. Naveed Ahmad, Connie J. Chen & David M. Aboulafia. (2023) Bowel, lung, and retinal ischemia: Rare manifestations of leukostasis syndrome in a man with chronic lymphocytic leukemia—A case report and review of the literature. Current Problems in Cancer: Case Reports 11, pages 100248.
Crossref
Crossref
Anne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, Lydia Campos, Michel Ticchioni, Marie-Sarah Dilhuydy, Stephane Morisset, Valérie Rouille, Béatrice Mahé, Kamel Laribi, Bruno Villemagne, Emmanuelle Ferrant, Olivier Tournilhac, Alain Delmer, Lysiane Molina, Véronique Leblond, Cécile Tomowiak, Sophie de Guibert, Frederique Orsini-Piocelle, Anne Banos, Philippe Carassou, Guillaume Cartron, Luc Mathieu Fornecker, Loic Ysebaert, Caroline Dartigeas, Margot Truchan-Graczyk, Jean-Pierre Vilque, Thérèse Aurran Schleinitz, Florence Cymbalista, Stéphane Leprêtre, Vincent Lévy, Florence Nguyen-Khac & Pierre Feugier. (2023) A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial. Blood Advances 7:15, pages 3936-3945.
Crossref
Crossref
Daniel Moreno Berggren, Hege Garelius, Petter Willner Hjelm, Lars Nilsson, Bengt Rasmussen, Caroline E. Weibull, Mats Lambe, Sören Lehmann, Eva Hellström-Lindberg, Martin Jädersten & Elisabeth Ejerblad. (2023) Therapy-related MDS dissected based on primary disease and treatment—a nationwide perspective. Leukemia 37:5, pages 1103-1112.
Crossref
Crossref
Shannon Nixon, Dominic Duquette, Sarah Doucette & Jean-Francois Larouche. (2023) How We Manage Patients with Indolent B-Cell Malignancies on Bruton’s Tyrosine Kinase Inhibitors: Practical Considerations for Nurses and Pharmacists. Current Oncology 30:4, pages 4222-4245.
Crossref
Crossref
Thi Thuy Nguyen, Nguyen Thanh Nhu, Van Khoi Tran, Tran Thuc Huan Nguyen & Chiou-Feng Lin. (2023) Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Monotherapy Compared with Combination Therapy for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Systematic Review and Meta-Analysis. Cancers 15:7, pages 1996.
Crossref
Crossref
Ofir Zavdy, Tara Coreanu, Dvir Yohai Bar-On, Amit Ritter, Gideon Bachar, Thomas Shpitzer, Noga Kurman, Muhammad Mansour, Dean Ad-El, Uri Rozovski, Gilad Itchaki, Shany Sherman, Limor Azulay-Gitter & Aviram Mizrachi. (2023) Cutaneous Squamous Cell Carcinoma in Immunocompromised Patients—A Comparison between Different Immunomodulating Conditions. Cancers 15:6, pages 1764.
Crossref
Crossref
Ana C. Oliveira, Josep Maria Roncero, Christelle Ferrá, Janilson Do Nascimento, Marta Rodriguez-Luaces, Maite Encuentra, Eva Domingo-Domenech, Patricia López, David Gallardo, Josep Maria Ribera, Josep Sarrá, Anna Sureda & Eva González-Barca. (2022) Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies. International Journal of Hematology 117:3, pages 388-397.
Crossref
Crossref
Esra Turan Erkek & Eda Aslan. (2023) Additional malignancies shorten overall survival in chronic lymphocytic leukemia irrespective of chromosomal aberrations: A retrospective cohort study. Medicine 102:6, pages e32906.
Crossref
Crossref
Zhumei Zhan, Wei Guo, Xin Wan & Ou Bai. (2023) Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors. Annals of Hematology 102:2, pages 249-259.
Crossref
Crossref
Lina van der Straten, Mark-David Levin, Manette A. W. Dinnessen, Otto Visser, Eduardus F. M. Posthuma, Jeanette K. Doorduijn, Anton W. Langerak, Arnon P. Kater & Avinash G. Dinmohamed. (2023) Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019. Blood Cancer Journal 13:1.
Crossref
Crossref
Thi Thuy Nguyen, Nguyen Thanh Nhu, Van Khoi Tran, Nguyen Van Cau & Chiou-Feng Lin. (2023) Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Plus Anti-CD20 Antibody Therapy Compared With Chemoimmunotherapy as Front-line Treatment for Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Journal of Immunotherapy Publish Ahead of Print.
Crossref
Crossref
Fruzsina Kósa, Tereza Nečasová, Martin Špaček, Krzysztof Giannopoulos, Iwona Hus, Tereza Jurková, Eva Koriťáková, Marika Chrápavá, Martina Nováčková, Ivana Katinová, Denisa Krejčí, Adam Jujka, Zoltán Mátrai, István Vályi‐Nagy, Tadeusz Robak & Michael Doubek. (2022)
Secondary malignancies and survival of
FCR‐treated
patients with chronic lymphocytic leukemia in Central Europe
. Cancer Medicine 12:2, pages 1961-1971.
Crossref
Crossref
Inhye E. Ahn & Jennifer R. Brown. (2022) Selecting initial therapy in CLL. Hematology 2022:1, pages 323-328.
Crossref
Crossref
Nadine Kutsch, Anna Maria Fink & Kirsten Fischer. (2022) Management of front line chronic lymphocytic leukemia. American Journal of Hematology 97:S2.
Crossref
Crossref
Tait D. Shanafelt, Xin Victoria Wang, Curtis A. Hanson, Elisabeth M. Paietta, Susan O’Brien, Jacqueline Barrientos, Diane F. Jelinek, Esteban Braggio, Jose F. Leis, Cong Christine Zhang, Steven E. Coutre, Paul M. Barr, Amanda F. Cashen, Anthony R. Mato, Avina K. Singh, Michael P. Mullane, Richard F. Little, Harry Erba, Richard M. Stone, Mark Litzow, Martin Tallman & Neil E. Kay. (2022) Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood 140:2, pages 112-120.
Crossref
Crossref
Maria‐Teresa Voso, Tatjana Pandzic, Giulia Falconi, Marija Denčić‐Fekete, Eleonora De Bellis, Lydia Scarfo, Viktor Ljungström, Michail Iskas, Giovanni Del Poeta, Pamela Ranghetti, Stamatia Laidou, Antonio Cristiano, Karla Plevova, Silvia Imbergamo, Marie Engvall, Antonella Zucchetto, Chiara Salvetti, Francesca R. Mauro, Niki Stavroyianni, Lucia Cavelier, Paolo Ghia, Kostas Stamatopoulos, Emiliano Fabiani & Panagiotis Baliakas. (2022) Clonal haematopoiesis as a risk factor for therapy‐related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo‐(immuno)therapy. British Journal of Haematology 198:1, pages 103-113.
Crossref
Crossref
Kamel Laribi, Alix Baugier de Materre, David Ghez, Caroline Dartigeas, Cécile Tomowiak, Béatrice Mahé, Jean-Baptiste Micol, Fatiha Merabet, Stéphane Leprêtre, Charles Herbaux, Loïc Ysebaert, Ronan Le Calloch, Lise Willems, Maud Voldoire, Damien Roos-Weil, Clotilde Bravetti, Yamina Touileb, Frédéric Davi, Florence Nguyen-Khac, Karim Maloum & Marie C. Béné. (2022) Therapy-related Myeloid Neoplasms in Patients With Chronic Lymphocytic Leukemia Who Received FCR/FC as Frontline Therapy. HemaSphere 6:6, pages e716.
Crossref
Crossref
M. Gauthier. (2022) La leucémie lymphoïde chronique. La Revue de Médecine Interne 43:6, pages 356-364.
Crossref
Crossref
Catherine Luedke, Yue Zhao, Jenna McCracken, Jake Maule, Lian-He Yang, Rachel Jug, Jonathan Galeotti, Imran Siddiqi, Jerald Gong, Chuanyi Mark Lu & Endi Wang. (2022) Myeloid neoplasms in the setting of chronic lymphocytic leukaemia/chronic lymphocytic leukaemia-like disease: a clinicopathological study of 66 cases comparing cases with prior history of treatment to those without. Journal of Clinical Pathology 75:5, pages 292-301.
Crossref
Crossref
Dale Jobson, Christopher J. McCormack, Victoria Mar, Constantine Tam & Michael A. Henderson. (2022) Impact of chronic lymphocytic leukaemia on melanoma outcomes: A retrospective case‐control study. British Journal of Haematology 197:3, pages 320-325.
Crossref
Crossref
Philip A. Thompson. (2022) SOHO State of the Art Updates and Next Questions: BTK inhibitors combined with chemoimmunotherapy in CLL, the best of both worlds?. Clinical Lymphoma Myeloma and Leukemia 22:4, pages 205-209.
Crossref
Crossref
Toby A. Eyre, Satoshi Hori & Talha Munir. (2021) Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management. Hematological Oncology 40:2, pages 129-159.
Crossref
Crossref
Yandong Shen, Luke Coyle, Ian Kerridge, William Stevenson, Christopher Arthur, Naomi McKinlay, Keith Fay, Christopher Ward, Matthew Greenwood, Oliver Giles Best, Ann Solterbeck, Alexander Guminski, Stephen Shumack & Stephen P. Mulligan. (2021) Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndrome. eJHaem 3:1, pages 129-138.
Crossref
Crossref
Nitin Jain, Philip Thompson, Jan Burger, Alessandra Ferrajoli, Koichi Takahashi, Zeev Estrov, Gautam Borthakur, Prithviraj Bose, Tapan Kadia, Naveen Pemmaraju, Koji Sasaki, Marina Konopleva, Elias Jabbour, Naveen Garg, Xuemei Wang, Rashmi Kanagal-Shamanna, Keyur Patel, Wei Wang, Jeffrey Jorgensen, Sa Wang, Wanda Lopez, Ana Ayala, William Plunkett, Varsha Gandhi, Hagop Kantarjian, Susan O’Brien, Michael Keating & William G. Wierda. (2021) Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia 35:12, pages 3421-3429.
Crossref
Crossref
Moritz Fürstenau, Adam Giza, Thomas Stumpf, Sandra Robrecht, Christian Maurer, Hartmut Linde, Lutz Jacobasch, Steffen Dörfel, Ali Aldaoud, Julia von Tresckow, Michael Koenigsmann, Tobias Gaska, Ulrich Kaiser, Hanns‐Detlev Harich, Kirsten Fischer, Barbara Eichhorst, Michael Hallek & Anna‐Maria Fink. (2021) Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia. American Journal of Hematology 96:12.
Crossref
Crossref
Nil Albiol, Miguel Arguello-Tomas & Carol Moreno. (2021) The road to chemotherapy-free treatment in chronic lymphocytic leukaemia. Current Opinion in Oncology 33:6, pages 670-680.
Crossref
Crossref
Carol Moreno, Cecilia Muñoz, María José Terol, José-Ángel Hernández-Rivas & Miguel Villanueva. (2021) Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively. Journal of Experimental & Clinical Cancer Research 40:1.
Crossref
Crossref
Maria Teresa Voso, Giulia Falconi & Emiliano Fabiani. (2021) What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms. Blood 138:9, pages 749-757.
Crossref
Crossref
Hua-Jay J. Cherng & Nitin Jain. (2021) First-Line Therapy for Chronic Lymphocytic Leukemia. Hematology/Oncology Clinics of North America 35:4, pages 725-738.
Crossref
Crossref
Hua‐Jay J. Cherng, Nadya Jammal, Shilpa Paul, Xuemei Wang, Koji Sasaki, Philip Thompson, Jan Burger, Alessandra Ferrajoli, Zeev Estrov, Susan O’Brien, Michael Keating, William G. Wierda & Nitin Jain. (2021) Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. British Journal of Haematology 194:1, pages 61-68.
Crossref
Crossref
Jan A. Burger. (2021) Integrating New Therapies for Chronic Lymphocytic Leukemia. The Cancer Journal 27:4, pages 275-285.
Crossref
Crossref
Inhye E. Ahn & Jennifer R. Brown. (2021) Targeting Bruton’s Tyrosine Kinase in CLL. Frontiers in Immunology 12.
Crossref
Crossref
Lucie Pehalova, Denisa Krejci, Jana Halamkova, Lenka Smardova, Lenka Snajdrova & Ladislav Dusek. (2021) Significant current epidemiological trend: Haematological malignancies as subsequent primary tumours in cancer patients. Cancer Epidemiology 72, pages 101929.
Crossref
Crossref
Rui Jiang, Jian-yong Li & Hua-yuan Zhu. (2021) Time-limited, Combined Regimen in Chronic Lymphocytic Leukemia: A Promising Strategy to Achieve a Drug Holiday. Current Medical Science 41:3, pages 431-442.
Crossref
Crossref
Meifang Zhao, Jingnan Sun, Shanshan Liu, Hongqiong Fan, Yu Fu, Yehui Tan & Sujun Gao. (2021) Development of a myelodysplastic/myeloproliferative neoplasm-unclassifiable in a patient with acute myeloid leukemia: a case report and literature review. Journal of International Medical Research 49:5, pages 030006052110184.
Crossref
Crossref
Natalia Timofeeva & Varsha Gandhi. (2021) Ibrutinib combinations in CLL therapy: scientific rationale and clinical results. Blood Cancer Journal 11:4.
Crossref
Crossref
Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, Ana P Gonzalez-Rodriguez, Ángel R. Payer, Esther González-García, Alejandro López-Soto & Segundo Gonzalez. (2021) BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia. Cancers 13:8, pages 1766.
Crossref
Crossref
Caspar da Cunha‐Bang, Klaus Rostgaard, Michael A. Andersen, Emelie C. Rotbain, Kirsten Grønbæk, Henrik Frederiksen, Carsten U. Niemann & Henrik Hjalgrim. (2021) Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population‐based study. British Journal of Haematology 193:2, pages 339-345.
Crossref
Crossref
Nicholas Chiorazzi, Shih-Shih Chen & Kanti R. Rai. (2021) Chronic Lymphocytic Leukemia. Cold Spring Harbor Perspectives in Medicine 11:2, pages a035220.
Crossref
Crossref
Carol Moreno. (2020) Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy. Hematology 2020:1, pages 33-40.
Crossref
Crossref
David A. Bond, Ying Huang, James L. Fisher, Amy S. Ruppert, Dwight H. Owen, Erin M. Bertino, Kerry A. Rogers, Seema A. Bhat, Michael R. Grever, Samantha M. Jaglowski, Kami J. Maddocks, John C. Byrd & Jennifer A. Woyach. (2020) Second cancer incidence in CLL patients receiving BTK inhibitors. Leukemia 34:12, pages 3197-3205.
Crossref
Crossref
Patrizia Mondello & Andrew D. Zelenetz. (2020) Reshaping the therapeutic landscape of chronic lymphocytic leukaemia in the era of targeted therapy. British Journal of Haematology 191:3, pages 326-328.
Crossref
Crossref
Amarendra Amar. (2021) Chronic lymphocytic leukemia and Second Primary Malignancies: A Relationship Revisited. Indian Journal of Medical and Paediatric Oncology 41:05, pages 787-788.
Crossref
Crossref
Jason C. Lee & Nicole Lamanna. (2020) Is There a Role for Chemotherapy in the Era of Targeted Therapies?. Current Hematologic Malignancy Reports 15:2, pages 72-82.
Crossref
Crossref
William George Wierda & Francesco Paolo Tambaro. (2020) How I Manage CLL with Venetoclax-Based Treatments. Blood.
Crossref
Crossref
G. A. Belitskiy, K. I. Kirsanov, E. A. Lesovaya & M. G. Yakubovskaya. (2020) Drug-Related Carcinogenesis: Risk Factors and Approaches for Its Prevention. Biochemistry (Moscow) 85:S1, pages 79-107.
Crossref
Crossref
Nadine Kutsch, Jasmin Bahlo, Sandra Robrecht, Jeremy Franklin, Can Zhang, Christian Maurer, Nisha De Silva, Elisabeth Lange, Rudolf Weide, Michael G. Kiehl, Martin Sökler, Rudolf Schlag, Ursula Vehling-Kaiser, Georg Köchling, Christoph Plöger, Michael Gregor, Torben Plesner, Marco Herling, Kirsten Fischer, Hartmut Döhner, Michael Kneba, Clemens-Martin Wendtner, Wolfram Klapper, Karl-Anton Kreuzer, Sebastian Böttcher, Stephan Stilgenbauer, Anna Maria Fink, Michael Hallek & Barbara Eichhorst. (2020) Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG). HemaSphere 4:1, pages e336.
Crossref
Crossref
Vivek Kumar, Sikander Ailawadhi, Leyla Bojanini, Aditya Mehta, Suman Biswas, Taimur Sher, Vivek Roy, Prakash Vishnu, Julian Marin-Acevedo, Victoria R. Alegria, Aneel Paulus, Sonikpreet Aulakh, Madiha Iqbal, Rami Manochakian, Winston Tan, Asher Chanan-Khan & Meghna Ailawadhi. (2019) Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer Journal 9:10.
Crossref
Crossref
Tait D. ShanafeltXin V. WangNeil E. KayCurtis A. HansonSusan O’BrienJacqueline BarrientosDiane F. JelinekEsteban BraggioJose F. LeisCong C. ZhangSteven E. CoutrePaul M. Barr, Amanda F. CashenAnthony R. MatoAvina K. SinghMichael P. MullaneRichard F. LittleHarry ErbaRichard M. StoneMark LitzowMartin Tallman. (2019) Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. New England Journal of Medicine 381:5, pages 432-443.
Crossref
Crossref
Jason P. Cooper, Sirin Khajaviyan, Stephen D. Smith, David G. Maloney, Andrei R. Shustov, Edus H. Warren, Lorinda A. Soma, Ryan C. Lynch, Chaitra Ujjani, Brian Till, Anna B. Halpern, Ajay K. Gopal, H. Joachim Deeg, Bart L. Scott & Mazyar Shadman. (2019) Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience. Clinical Lymphoma Myeloma and Leukemia 19:6, pages 390-395.
Crossref
Crossref
Taha Al-Juhaishi, Arushi Khurana & Danielle Shafer. (2019) Therapy-related myeloid neoplasms in lymphoma survivors: Reducing risks. Best Practice & Research Clinical Haematology 32:1, pages 47-53.
Crossref
Crossref
Adalgisa Condoluci & Davide Rossi. 2019. Chronic Lymphocytic Leukemia. Chronic Lymphocytic Leukemia
137
151
.
Nitin Jain. (2018) Selecting Frontline Therapy for CLL in 2018. Hematology 2018:1, pages 242-247.
Crossref
Crossref
Rouslan Kotchetkov, Robert El-Maraghi & Leena Narsinghani. (2018) Leukoerythroblastosis with Cytopenia as an Initial Presentation of Lung Adenocarcinoma. Case Reports in Oncology 11:2, pages 567-572.
Crossref
Crossref
Jan A. Burger & Susan O’Brien. (2018) Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy. Nature Reviews Clinical Oncology 15:8, pages 510-527.
Crossref
Crossref
Davide Rossi, Valeria SpinaGianluca Gaidano. (2018) Biology and treatment of Richter syndrome. Blood 131:25, pages 2761-2772.
Crossref
Crossref
Nitin JainPhilip ThompsonAlessandra FerrajoliChadi NabhanAnthony R. MatoSusan O’Brien. (2018) Approaches to Chronic Lymphocytic Leukemia Therapy in the Era of New Agents: The Conundrum of Many Options. American Society of Clinical Oncology Educational Book:38, pages 580-591.
Crossref
Crossref
Jennifer Gill & Mitchell E. Hughes. (2018) Primer on Chronic Lymphocytic Leukemia: Part I. The Journal for Nurse Practitioners 14:4, pages 302-308.
Crossref
Crossref
Michael Hallek, Tait D Shanafelt & Barbara Eichhorst. (2018) Chronic lymphocytic leukaemia. The Lancet 391:10129, pages 1524-1537.
Crossref
Crossref
Craig S. Boddy & Shuo Ma. (2018) Frontline Therapy of CLL: Evolving Treatment Paradigm. Current Hematologic Malignancy Reports 13:2, pages 69-77.
Crossref
Crossref
Gilad Itchaki & Jennifer R. Brown. (2017) Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia. Therapeutic Advances in Hematology 9:1, pages 3-19.
Crossref
Crossref
J R Brown, P Hillmen, S O’Brien, J C Barrientos, N M Reddy, S E Coutre, C S Tam, S P Mulligan, U Jaeger, P M Barr, R R Furman, T J Kipps, F Cymbalista, P Thornton, F Caligaris-Cappio, J Delgado, M Montillo, S DeVos, C Moreno, J M Pagel, T Munir, J A Burger, D Chung, J Lin, L Gau, B Chang, G Cole, E Hsu, D F James & J C Byrd. (2017) Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia 32:1, pages 83-91.
Crossref
Crossref
Jennifer R. Brown & Neil E. Kay. (2017) Reply to S. Opat et al. Journal of Clinical Oncology 35:36, pages 4094-4095.
Crossref
Crossref
Kirsten Fischer & Michael Hallek. (2017) Optimizing frontline therapy of CLL based on clinical and biological factors. Hematology 2017:1, pages 338-345.
Crossref
Crossref
Erlene K. Seymour, Charles A. Schiffer & Jonas A. de Souza. (2017) Challenges in the Clinical Application of the American Society of Clinical Oncology Value Framework: A Medicare Cost-Benefit Analysis in Chronic Lymphocytic Leukemia. Journal of Oncology Practice 13:12, pages e1002-e1011.
Crossref
Crossref
Ning Ren, Manar Atyah, Wan-Yong Chen & Chen-Hao Zhou. (2017) The various aspects of genetic and epigenetic toxicology: testing methods and clinical applications. Journal of Translational Medicine 15:1.
Crossref
Crossref
Prajwal Boddu, Ellen Schlette, Beenu Thakral, Guillin Tang, Naveen Pemmaraju, Tapan Kadia, Alessandra Ferrajoli, Farhad Ravandi, William Wierda & Nitin Jain. (2017) Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia—A case report. Hematology/Oncology and Stem Cell Therapy.
Crossref
Crossref
Abdallah Abou Zahr, Ami M. Kavi, Sudipto Mukherjee & Amer M Zeidan. (2017) Therapy-related myelodysplastic syndromes, or are they?. Blood Reviews 31:3, pages 119-128.
Crossref
Crossref
A. Cuneo & R. Foà. (2017) Management of CLL in the elderly. Annals of Oncology 28:2, pages 200-204.
Crossref
Crossref
Andrea Visentin, Silvia Imbergamo, Carmela Gurrieri, Federica Frezzato, Valentina Trimarco, Veronica Martini, Filippo Severin, Flavia Raggi, Edoardo Scomazzon, Monica Facco, Francesco Piazza, Gianpietro Semenzato & Livio Trentin. (2017) Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients. European Journal of Cancer 72, pages 103-111.
Crossref
Crossref
Erin M. Pettijohn & Shuo Ma. (2017) Targeted Therapy in Chronic Lymphocytic Leukemia (CLL). Current Hematologic Malignancy Reports 12:1, pages 20-28.
Crossref
Crossref
Prithviraj Bose & Varsha Gandhi. (2017) Recent therapeutic advances in chronic lymphocytic leukemia. F1000Research 6, pages 1924.
Crossref
Crossref
Pablo Mozas & Julio Delgado. (2016) Avances en el tratamiento de la leucemia linfoc?tica cr?nica. Medicina Cl?nica 147:10, pages 447-454.
Crossref
Crossref
Pablo Mozas & Julio Delgado. (2016) Advances in the treatment of chronic lymphocytic leukaemia. Medicina Cl?nica (English Edition) 147:10, pages 447-454.
Crossref
Crossref
Adrian Wiestner. (2016) Choosing frontline chemoimmunotherapy for CLL. The Lancet Oncology 17:7, pages 852-854.
Crossref
Crossref
Barbara Eichhorst, Anna-Maria Fink, Jasmin Bahlo, Raymonde Busch, Gabor Kovacs, Christian Maurer, Elisabeth Lange, Hubert Köppler, Michael Kiehl, Martin Sökler, Rudolf Schlag, Ursula Vehling-Kaiser, Georg Köchling, Christoph Plöger, Michael Gregor, Torben Plesner, Marek Trneny, Kirsten Fischer, Harmut Döhner, Michael Kneba, Clemens-Martin Wendtner, Wolfram Klapper, Karl-Anton Kreuzer, Stephan Stilgenbauer, Sebastian Böttcher & Michael Hallek. (2016) First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. The Lancet Oncology 17:7, pages 928-942.
Crossref
Crossref
L. Falchi, C. Vitale, M.J. Keating, S. Lerner, X. Wang, K.Y. Elhor Gbito, S. Strom, W.G. Wierda & A. Ferrajoli. (2016) Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia. Annals of Oncology 27:6, pages 1100-1106.
Crossref
Crossref
Jennifer R. BrownMichael J. HallekJohn M. Pagel. (2016) Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?. American Society of Clinical Oncology Educational Book:36, pages e387-e398.
Crossref
Crossref
Davide Rossi & Gianluca Gaidano. (2016) Richter syndrome: pathogenesis and management. Seminars in Oncology 43:2, pages 311-319.
Crossref
Crossref
Kanti R. Rai & Preetesh Jain. (2016) Chronic lymphocytic leukemia (CLL)-Then and now. American Journal of Hematology 91:3, pages 330-340.
Crossref
Crossref
Krzysztof Lewandowski, Micha? Gniot, Maria Lewandowska, Anna Wache, B?a?ej Ratajczak, Anna Czy?, Ma?gorzata Jarmu?-Szymczak & Mieczys?aw Komarnicki. (2016) B-Cell Chronic Lymphocytic Leukemia with 11q22.3 Rearrangement in Patient with Chronic Myeloid Leukemia Treated with Imatinib. Case Reports in Medicine 2016, pages 1-6.
Crossref
Crossref
Jan A. Burger, Alessandra Tedeschi, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Osnat Bairey, Peter Hillmen, Nancy L. Bartlett, Jianyong Li, David Simpson, Sebastian Grosicki, Stephen Devereux, Helen McCarthy, Steven Coutre, Hang Quach, Gianluca Gaidano, Zvenyslava Maslyak, Don A. Stevens, Ann Janssens, Fritz Offner, Ji?? Mayer, Michael O?Dwyer, Andrzej Hellmann, Anna Schuh, Tanya Siddiqi, Aaron Polliack, Constantine S. Tam, Deepali Suri, Mei Cheng, Fong Clow, Lori Styles, Danelle F. James & Thomas J. Kipps. (2015) Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. New England Journal of Medicine 373:25, pages 2425-2437.
Crossref
Crossref
Davide RossiLodovico Terzi-di-BergamoLorenzo De PaoliMichaela CerriGuido GhilardiAnnalisa ChiarenzaPietro BulianCarlo ViscoFrancesca R. MauroFortunato MorabitoAgostino CortelezziFrancesco ZajaFrancesco ForconiLuca LaurentiIlaria Del GiudiceMassimo GentileIolanda VincelliMarina MottaMarta CosciaGian Matteo RigolinAlessandra TedeschiAntonino NeriRoberto MarascaOmar PerbelliniCarol MorenoGiovanni Del PoetaMassimo Massaia, Pier Luigi Zinzani, Marco MontilloAntonio CuneoValter GatteiRobin FoàGianluca Gaidano. (2015) Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood 126:16, pages 1921-1924.
Crossref
Crossref